Vaxcyte, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the Annual Meeting of Stockholders held by Vaxcyte, Inc. on June 15, 2026. The filing details the voting results for director elections, auditor ratification, and executive compensation.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
The following matters were submitted to a vote of security holders:
- Director Elections (Class III): Three nominees were re-elected to serve until the 2029 Annual Meeting.
- Olivier Brandicourt, M.D.: 116,370,183 For; 16,643,897 Withheld.
- Halley Gilbert, J.D.: 114,704,274 For; 18,309,806 Withheld.
- Grant Pickering, M.B.A.: 132,112,840 For; 901,240 Withheld.
- Auditor Ratification: Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Votes: 137,230,032 For; 137,589 Against; 862 Abstain.
- Executive Compensation (Say-on-Pay): The non-binding advisory resolution was approved.
- Votes: 130,011,017 For; 2,755,868 Against; 247,195 Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the total number of shares outstanding to calculate the percentage of votes cast for each proposal.
- Confirm the specific terms of the re-elected directors' tenure through the 2029 Annual Meeting.
- Note the significant number of broker non-votes (4,354,403) recorded for the director elections and say-on-pay vote.
- Review the full proxy statement for detailed biographies of the re-elected directors and the rationale for the executive compensation package.